which contains the catalytic activity. In somatic cells Pol is an essential enzyme of the base excision repair (BER) and single strand break (SSB) repair pathways (Hubscher et al., 2002) .
We also demonstrated (Bergoglio et al., 2001; Canitrot et al., 1998) that Pol overexpression allows cells to tolerate bifunctional DNA damage generated for example by cisplatin, which is used in the treatment of many cancers (Pil and Lippard, 1997) . Indeed Pol facilitates the error-prone translesion replication of these adducts which otherwise would block the replicative machinery and kill the cells (Canitrot et al., 1998; Hoffmann et al., 1995) . A large number of mechanisms can contribute to cisplatin resistance such as decreased drug uptake, enhanced repair of the adducts or increased levels of detoxifying agents like glutathione (Andrews and Howell, 1990) . The resistant phenotype of 2008 C13*5.25 cells used in this study, generated from 2008 human ovarian carcinomas by in vitro selection with cisplatin (Andrews et al., 1985) has been attributed to impaired uptake, decreased DNA platination (Jekunen et al., 1994) , as well as translesion synthesis across cisplatin adducts. Such replicative bypass has been measured either indirectly by quantifying radiolabeled nascent DNA (Mamenta et al., 1994) or more directly by showing that extracts from these cells displayed an enhanced Pol -mediated capacity to replicate a DNA oligonucleotide carrying a cisplatin adduct (Bergoglio et al., 2001 ). Moreover, down-regulation of pol by siRNA clearly sensitised cisplatin-resistant Hela and SKOV-3 cancer cells to cisplatin (M. Albertella, KuDOS, UK, communicated in J. Monod conference, Roscoff, 2004) . 5 In addition to its contribution to the mutagenic translesion process, up-regulated Pol induces an overall untargeted genetic instability by competing with replicative DNA polymerases in DNA transactions where normally it is not involved (Canitrot et al., 2000; Servant et al., 2002a) . It thus contributes to the emergence of variant clones with a proliferating phenotype (Bergoglio et al., 2003; Bergoglio et al., 2002; Canitrot et al., 1998; Canitrot et al., 1999; Servant et al., 2002a) . In accordance with these data, inhibition of Polmediated DNA synthesis by using dideoxycytidine, which is efficiently incorporated into DNA by this enzyme (Copeland et al., 1992) , increased the survival of mice previously inoculated with Pol -overexpressing melanomas (Louat et al., 2001 ).
Pol shares infidelity and TLS capacity with the newly-discovered error-prone DNA polymerases such as Pol , , , and (Radman, 1999) , which seem also devoted in vivo to help cells to tolerate DNA damage. Among those "adaptive" DNA polymerases, Pol whose primary sequence is very close to that of Pol also possesses an intrinsic 5'-deoxyribose-5'-phosphate lyase function (Garcia-Diaz et al., 2001 ) and a distributive DNA synthesis activity (Garcia-Diaz et al., 2002) . Moreover Pol can substitute in vitro Pol in BER, suggesting that it also participates to this pathway (Garcia-Diaz et al., 2001) . In this work we have searched for natural compounds that can selectively inhibit Pol as i) tools to investigate its specific role in vivo by distinguishing it from other DNA polymerases such as replicative or beta-like DNA polymerase and ii) new potential drugs likely to reverse the Pol -associated tumor resistance to cisplatin. To our knowledge, only two Pol inhibitors have been considered to-date as specific i.e. prunasin (IC 50 of 93µM), isolated from a red Perila and a mugwort (Mizushina et al., 1999) and solanapyrone A (IC 50 of 30µM), a plant phytotoxin (Mizushina et al., 2002 
Material and Methods
Plant extracts and compounds. Extracts from either the stems of J. communis and P.
lentiscus or the leaves of M. palustris were prepared by overnight maceration in ethyl acetate
(1/10 w/v), filtration and evaporation. These extracts (50 mg) were first coarsely fractionated on 1.5 mg (6ml) SPE SiO 2 cartridges Upti-clean (Interchim) using hexane, and a gradient of methanol in chloroform as eluents. Aliquots were dissolved in 100% DMSO and diluted 1/1200 in the enzyme assay. Then 50 g of the plant material were submitted to a bioguided fractionation by combining chromatographies (normal and reverse C18 phases) to lead respectively to 50 mg of CA, 60 mg of MA and 400 mg of MH as pure compounds. These products were dissolved in appropriated buffer to achieve 10 -2 M to 10 -7 M solutions.
Cells and cell extracts. The pol null and the corresponding wild-type mouse embryonic fibroblasts (MEF) were purchased from ATCC and described previously (Sobol et al., 1996) . They were cultivated in DMEM. Human 2008 and 2008 C13*5.25 cells were grown as described in RPMI1640 medium (Bergoglio et al., 2001 ). HeLa cells (ATCC) were grown as spinner cultures in the same medium. Replicative extracts were prepared from either Hela or MEF cells as described (Roberts et al., 1993) after harvesting cells in the upper part of their log phase growth.
Enzymes. Rat Pol for the HTS was purified as described (Skandalis and Loeb, 2001 ).
The 8-kDa domain of human Pol (residues 1-88) was cloned into pIVEX2.4d (Roche) to obtain the p1968 plasmid which was sequenced and introduced into BL21(DE3) bacteria before purification as described (Skandalis and Loeb, 2001 ). Purification of Pol was carried out by GTP Technology (Toulouse, France). Human Pol for replication assays was purchased from Trevigen (USA). Pol was purchased from ChimerX. The recombinant four subunits of Pol were isolated from infected insect baculovirus Sf9 cells as described (Podust et al., 2002) . Full length recombinant single subunit Pol have been purified according to Ramadan et al. (Ramadan et al., 2003) . Purification of the Human Immunodeficiency Virus reverse transcriptase (HIV RT) was as published (Preston et al., 1988) . 
Micro

DNA replication assay
Cell extracts preparation and replication conditions for these extracts were previously described (Servant et al., 2002a) . All purified DNA polymerases were tested by using specific conditions for their optimal activity. One unit of DNA polymerase corresponds to 1 pmol of dNTP incorporated into acid-insoluble materials at 37°C in 60 min, by using as a substrate an activated calf thymus DNA pre-incubated with DNAse I. Calf thymus DNA pre-incubated with DNase I (activated DNA from Sigma) was used as a template in a final volume of 20 l at 37°C for various incubation times in the presence of inhibitors. Human Pol (0.5 units)
was added to a reaction buffer containing 25 mM Hepes KOH pH 8.5, 10mM MgCl 2 , 25 mM NaCl, 1mM DTT, 100 µM of each dATP, dGTP, dCTP, 0.2 µCi dTTP and 1 g template. and 1 g template. The amounts of DNA polymerases were chosen in order to obtain comparable nucleotide incorporation without inhibitor. After incubation, reaction was stopped with 10 mM EDTA and the radioactive DNA products were collected on GF/C glass fibre filters (Whatman). Filters were washed twice with 0.5% TCA solution and then used for determination of radioactivity. IC 50 was calculated by using GraphPad Prism software (San Diego, CA).
Docking of masticadienonic acid on human DNA polymerase
Molecular modelling was performed by using SYBYL 6.9 (from TRIPOS Inc., St Louis, MO) by running on a Silicon Graphics Octane2 workstation. Docking calculations were performed utilising FlexX, version1.11. The FlexX scoring function was used during the complex construction phase. DrugScore as implemented in FlexX reranked the obtained solutions. Thirty docking solutions were generated. These solutions were checked to find the solution with the best score that matched the original pharmacophore hypothesis. Figures were generated using Grasp (Nicholls et al., 1991) or Pymol (http://www.pymol.org).
Translesion synthesis assay
The unmodified or cisplatin-modified 60-mer template were prepared as described (Hoffmann et al., 1995) and hybridised to a 5'-32 P-labeled 17-mer primer. Translesion reactions were carried out as described (Bergoglio et al., 2001) . At the end of the reaction, the samples were denatured for 10 min at 70°C and loaded onto a 15 % polyacrylamide / 7 M urea / 30 % formamide gel.
Proliferation and clonogeny assays
For growth rate analysis, the control MEF and MEF pol -/-cells were seeded at 300
and 600 cells per well in 6-well dishes, respectively. Cells were allowed to attach overnight at 34°C in a MEM medium supplemented with glutamine/10% foetal calf serum/penicillin/streptomycin and treated with cisplatin (Sigma) for 1h at 37°C and /or masticadienonic acid at various concentrations during 6 days. Cells were then trypsinised and counted. Cellular proliferation was expressed as the ratio of the cell number in the untreated wells versus that in the treated wells.
Cytotoxicity for the 2008 and 2008/C13 5.25 cells was determined by a clonogenic assay as described (Bergoglio et al., 2001 ). For resistance reversion assays, cells were treated with inhibitors at DL 20 all experiment long, cisplatin (Sigma) being administrated for 1h at 37°C 24h after plating.
Results
High throughput screening (HTS) of partially purified plant extracts.
An automated assay was designed to identify Pol inhibitors by selecting compounds that decreased the incorporation of fluorescent nucleotides into a DNA template. The ddCTP chain terminator, which inhibits DNA synthesis mediated by Pol (Bouayadi et al., 1997) was used as a reference (Fig. 1A) . The "z' factor" determination proposed by Zhang et al (Zhang et al., 1999) is an indicator of the performance of the assay system. In the present case we measured a z' factor average value of 0. 55. During the run, the interplate coefficient of variability (CV) of the DMSO control signal value averaged 7.5 % (data not shown). This simple assay enabled the screening of 8,448 partially purified natural extract fractions, from which 71 active extracts were identified. Subsequent 32 P-labelled-primer extension procedure was carried out with Pol and replicative CHO cell extracts to select specific inhibitory extracts. Three of them were selected ( Fig 1A) : Juniperus communis (EX1), Pistacia lentiscus (EX2), and Mahurea palustris (EX3) from which we isolated and purified the corresponding active molecules, trans-communic acid, masticadienonic acid and mahureone A, respectively.
Structural characterization of the three inhibitors
The compound isolated from Juniperus communis (Cupressaceae) was found to be a ubiquitous diterpene of the labdane series: trans communic acid (CA). Its structure (Fig. 1B) was established by comparison of its spectral data (1 and 2D NMR and MS) with that from an authentic sample (Arya et al., 1961) . A second molecule was isolated in a straightforward manner from Pistacia lentiscus (Anarcardiaceae), a small tree growing in the Mediterranean basin and the exudate of which, known as mastic, is used as a chewing gum. The active compound was found to be masticadienonic acid (MA), 3-oxotirucalla-7, 24-dien-26-oic acid, for which the structure (Fig. 1C) was known (Barton and Soane, 1956) . Worthy of note is the mu fact that the isomer isomasticadienonic acid, also present in the extract, which only differs by the position of the double bond in ring B ( 7 vs. 8) is totally inactive in the test (data not shown). The structure is also very close to another Pol inhibitor isolated by Hecht et al. which is characterised by a rare E double bond in the chain (Deng et al., 2000) . The Z configuration of the 24 double bond in the mastic compound was ascertained by the NMR chemical shift of H-24 (6.10-ppm vs. 6.89 in the E compound). The third product was isolated from a plant from Guyana Mahurea palustris, a species belonging to the Guttiferae family and which has so far not been the object of chemical investigations. Mass spectrometry indicated that this molecule, for which we propose the trivial name of mahureone A (MH), had a C 35 H 46 O 6 composition (exact mass analysis) and the molecular ion was characterised by its decomposition with losses of 69 (isoprene chain) and 128 mass units. UV was not very informative and simply indicated the presence of a phenyl ring ( max 283 nm) while IR displayed vibrations for a complex carbonyl system. Literature search showed a compound, laxifloranone (Fig. 2B) , also isolated from a Guttiferae, Marila laxiflora, with similar data (Bokesch et al., 1999) but direct comparison of the compounds on HPLC proved that they were different. The 1 H and 13 C NMR spectra and full analysis of 2D NMR experiments led to the proposed structure (Fig. 1D) , salient feature of which being the central six member ring which contained a rare triketone (enolised form) and no less than eight contiguous quaternary carbon atoms. The validity of the structure was further supported by the isolation of four other compounds from the same series (data not shown). The differences between mahureone A and laxifloranone may be explained by a ring opening in basic medium followed by ring closure of an intermediate enol in a series of events compatible with the rule of the biosynthesis. They most probably belong to the same optical series.
Effect of CA, MA and MH on DNA polymerase , other DNA polymerases and replicative nuclear extracts.
To assess the efficiency of the three inhibitors on Pol , we carried out an in vitro replication assay by using an activated gapped genomic DNA. DNA synthesis signals obtained with Pol were compared to that of nuclear extracts from HeLa cells, which contain all the replicative DNA polymerases able to support bi-directional and semi-conservative genomic DNA replication, as well as to the purified replicative Pol and the error-prone Pol and Pol . As shown in Fig. 2 (A-C) (Fig. 2 A-C) .
We also tested the inhibitory action of MA on the other replicative enzyme Pol involved in the synthesis of RNA/DNA primers, and found that this enzyme is less affected (IC 50 of 93 M) than Pol (Fig. 2 B) . Taken together, these data indicate that masticadienonic acid (MA)
is an attractive Pol inhibitor.
Effect of MA on pol null cells
Although pol -deficient null mice are not viable (Sugo et al., 2000) , suggesting that correctly performed BER is highly important for maintaining development, the corresponding embryonic cells survive in culture (Sobol et al., 1996) . However, p is likely required in responding to endogenous oxidative genotoxic stress (Horton et al., 2002) , and we predicted that inhibition of this enzyme in cells would affect their survival as compared to wild type cells grown in the same conditions. Therefore, we used a pol knockout mice fibroblast cell line and its isogenic control wild type cell and conducted growth analysis for both cell lines in the absence or presence of the inhibitor during 6 days. We found that cells lacking Pol are less sensitive to MA as compared to the control cells, suggesting an alteration of essential Pol -mediated DNA transactions (BER or SSB repair). This is illustrated in cellular proliferation experiments as a function of dose of MA shown in Fig 2D. As an additional control we also measured the MA activity on replicative MEF and MEF pol -/-cell extracts and found that both extracts are resistant to MA (Table 1) , probably because Pol at a basal level does not belong to the replication machinery. From this experiment, we suggest that MA could alter the Pol -mediated process of endogenous oxidative DNA damage.
MA best fits the ssDNA binding site of the 8-kDa domain of DNA polymerase
The crystal and solution structure of the human Pol have been determined (Maciejewski et al., 2000; Sawaya et al., 1997) . We used the Pol pdb file 1BPY without DNA to dock MA using FlexX. This software is designed to identify the positive charges likely to bind carboxylate. In silico analysis indicated that MA is likely to interact with the ssDNA binding site of the 8-kDa N-terminal domain of Pol (Fig. 3A-C) . Figure 3A shows the ssDNA-binding site of Pol in the presence of the ssDNA. Figure 3B shows MA alone in the ssDNA binding site of Pol Figure 3C represents the superposition of ssDNA and MA,
showing that the inhibitor interacts with Lys60, Lys68 and Lys35. Lys60 makes a hydrogen bond with MA and Lys68 and Lys35 make ionic contact with the carbonyl of MA. The distances between those residues and MA are 2.86, 2.85, 2.81 Å, respectively. Interestingly, Lys68 and Lys35 are known to be the main residues recognising directly ssDNA (Prasad et al., 1998) . We checked that the ssDNA-binding site of Pol does not differ in the absence of DNA by superposing the two structures (1BPY and 1DK3 without DNA, data not shown).
Moreover we found that MA does not bind the dNTP site of the active site in the palm domain and band shift assays indicated that MA interacts with the 8-kDa domain (data not shown), further suggesting a competitive inhibiting action of MA because of its association with the ssDNA-binding site.
Effect of the three inhibitors on the translesion synthesis (TLS) across a cisplatin adduct
In vitro, Pol efficiently replicates past a single Pt-(dGpG) lesion (Fig 4B ; compare lanes 1 and 2) during a 17-mer primer extension reaction on a platinated 60-mer template (Fig. 4A) . We investigated the impact of the inhibitors during this specific Pol -mediated bypass synthesis. We determined inhibitory concentrations able to affect the translesion synthesis (TLS) without inhibitory effect on undamaged DNA. As indicated in Fig 4B (lanes   3-8) , MA is the most effective TLS inhibitor since only 30 M MA were sufficient for altering the bypass (Fig. 4B, lanes 3-4) whereas the inhibition was achieved with 100 M CA and 200 M MH (Fig. 4B, lanes 5-8) . It has to be noted that the presence of the adduct changes the synthesis from distributive to processive in nature. We discussed this aspect in previous papers (Hoffmann et al., 1996; Hoffmann et al., 1995) , explaining that when the damage is present, the enzyme dissociates frequently from the adducted bases, resulting in more availability of Pol to re-initiate primer extension and to extend most of the termini to the site of the lesion. Further, the synthesis upstream the lesion is not altered in the presence of inhibitors. However concentrations of the inhibitors used for this TLS experiment could not be compared to those used in the calf thymus activated DNA assay (Fig 2) since the nature of DNA substrates are different and the ratio [Pol / 3'hydroxy termini of the DNA substrate] is much lower in the latter case.
Cell resistance to cisplatin in the presence of inhibitors
We previously demonstrated (Bergoglio et al., 2001 ) that a Pol -dependent TLS across platinated DNA crosslinks occurred in the 2008C13*5.25 human tumour cells, known to display a tolerant phenotype towards cisplatin. We proposed that this TLS process could contribute to the cisplatin resistance phenotype exhibited by these cells as compared to the parental 2008 cells (Bergoglio et al., 2001) . The potential of the three inhibitors to prevent Pol from bypassing a cisplatin adduct in vitro prompted us to examine whether they could reduce the resistance to cisplatin of the 2008C13*5.25 cells. Clonogenic experiments were performed by incubating the cells with both cisplatin and a sublethal (80% cell survival) concentration of inhibitors (Fig 4C) . In the presence of MA, the strongest TLS inhibitor in vitro, we observed a significant sensitization of 2008 C13*5.25 cells to cisplatin while the response of parental 2008 cells to cisplatin was not altered. In contrast, MA and MH, which were less efficient for inhibiting TLS in vitro (see Fig. 4B ), had poor effect.
Finally we wondered whether the deletion of pol had any impact on the ability of MA to sensitize the cells to cisplatin. Fig. 4D indicates that the response of pol minus MEF cells to cisplatin was not modified by the presence of MA, whereas such response is altered in wild-type MEF cells, cisplatin survival of pol +/+ cells treated with MA being similar to that of pol minus cells. These data are in accordance with another study recently published,
showing that a synthetic Pol inhibitor did not affect the sensitivity of pol knockout MEF cells to MMS whereas it alters the cell survival of wild-type cells (Hu et al., 2004) . Our results further reinforce the in vitro findings showing the specific anti-Pol inhibitory action of MA.
Discussion
We described here the identification of three new natural molecules that inhibited Pol an error-prone enzyme frequently overexpressed in tumor cells (Canitrot et al., 2000; Scanlon et al., 1989; Servant et al., 2002b; Srivastava et al., 1999) . Among those molecules,
we identified a product that we named mahureone A since it was purified from the leaves of Mizushina et al., 1999) . Our study reports a natural compound whose inhibitory action is more potent and preferentially targets Pol compared to a wide range of other DNA polymerases. This was confirmed by using a poldeficient null embryonic cell line, which was less sensitive to the action of MA than its isogenic wild type cell line. Therefore, masticadienonic acid can be considered as a potential useful molecular tool for investigating the role of Pol among all the X-family DNA polymerases in normal somatic cells, for example in helping to distinguish its specific role in base excision repair pathway from Pol .
The anticancer agent cisplatin is widely used in the treatment of ovarian, testicular, head and neck carcinomas. Its therapeutic effects result from covalent binding to DNA thus inhibiting replication and/or transcription (Pil and Lippard, 1997) . Nevertheless, the cisplatin lesions are also mutagenic and could thus play a role in the generation of second tumours in cancer patients treated with this agent. Another major obstacle for the successful treatment of cancer by cisplatin is drug resistance. Most of the studies on platinum resistance have focused on decreased drug uptake, enhanced nucleotide excision repair, or loss of DNA mismatch repair (Andrews and Howell, 1990) . It has also been proposed that an alternative tumor resistance may be due to an increased capacity of the cell to tolerate platinum-DNA lesions.
We (Canitrot et al., 1998; Hoffmann et al., 1995) and others (Vaisman and Chaney, 2000; Vaisman et al., 1999) have shown that Pol has the potential to efficiently catalyse errorprone translesion synthesis in vitro across the major intrastrand cross-link at the N-7 positions of adjacent guanine bases. In addition to alternative mechanisms such as drug uptake and DNA platination (Jekunen et al., 1994) this translesion mechanism has been proposed to contribute to the cisplatin resistance of the human ovarian carcinoma 2008/C13 5.25 cells (Bergoglio et al., 2001; Mamenta et al., 1994) , extracts from these cells displaying enhanced replicative bypass and Pol -mediated translesion synthesis of platinum lesions. We found here that the three selected inhibitors affect the in vitro ability of Pol to bypass a cisplatin adduct, MA being the most potent. As a consequence, we showed that MA decreased the ability of 2008/C13 5.25 to adapt to cisplatin pressure. In contrast MA did not affect the response to cisplatin of MEF pol -/-cells and confers to wild-type cells a pol -/-phenotype of resistance to cisplatin. Surprisingly, we also observed in the control experiments that MA protected from cisplatin toxicity wild-type MEF cells, known to be sensitive to this agent (Raaphorst et al., 2002) . 
